| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydatidiform Mole | 140 | 2024 | 255 | 22.030 |
Why?
|
| Uterine Neoplasms | 195 | 2024 | 1420 | 16.220 |
Why?
|
| Chorionic Gonadotropin | 75 | 2024 | 457 | 5.800 |
Why?
|
| Choriocarcinoma | 42 | 2022 | 121 | 4.690 |
Why?
|
| Trophoblastic Neoplasms | 68 | 2000 | 88 | 4.470 |
Why?
|
| Methotrexate | 39 | 2024 | 1716 | 4.440 |
Why?
|
| Ovarian Neoplasms | 143 | 2021 | 4849 | 3.750 |
Why?
|
| Pregnancy | 277 | 2024 | 29868 | 3.660 |
Why?
|
| Vacuum Curettage | 7 | 2021 | 44 | 2.640 |
Why?
|
| Dactinomycin | 28 | 2024 | 304 | 2.560 |
Why?
|
| Trophoblastic Tumor, Placental Site | 8 | 2024 | 20 | 2.170 |
Why?
|
| Brazil | 18 | 2023 | 1228 | 2.130 |
Why?
|
| Hysterectomy | 30 | 2024 | 856 | 2.060 |
Why?
|
| Placenta | 26 | 2022 | 1709 | 1.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 48 | 2024 | 11736 | 1.900 |
Why?
|
| Antimetabolites, Antineoplastic | 10 | 2020 | 645 | 1.540 |
Why?
|
| Pregnancy Outcome | 17 | 2021 | 2921 | 1.470 |
Why?
|
| Female | 478 | 2024 | 392148 | 1.400 |
Why?
|
| Pregnancy Complications, Neoplastic | 11 | 2017 | 258 | 1.380 |
Why?
|
| Neoplasm Staging | 73 | 2021 | 11116 | 1.360 |
Why?
|
| Neoplasms, Glandular and Epithelial | 14 | 2018 | 487 | 1.260 |
Why?
|
| Uterine Hemorrhage | 11 | 2017 | 240 | 1.260 |
Why?
|
| Leucovorin | 18 | 2021 | 643 | 1.210 |
Why?
|
| Etoposide | 15 | 2024 | 634 | 1.130 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 14 | 2015 | 81 | 1.100 |
Why?
|
| Cystadenocarcinoma, Serous | 19 | 2020 | 473 | 1.060 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2018 | 284 | 1.050 |
Why?
|
| Trophoblasts | 11 | 2017 | 224 | 1.050 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2023 | 5304 | 1.020 |
Why?
|
| Humans | 482 | 2024 | 760617 | 0.950 |
Why?
|
| Fallopian Tube Neoplasms | 14 | 2020 | 328 | 0.940 |
Why?
|
| Neoplasm Recurrence, Local | 38 | 2023 | 9277 | 0.920 |
Why?
|
| Retrospective Studies | 91 | 2024 | 80566 | 0.890 |
Why?
|
| Maternal Age | 6 | 2016 | 809 | 0.880 |
Why?
|
| Watchful Waiting | 2 | 2017 | 491 | 0.840 |
Why?
|
| New England | 16 | 2017 | 1051 | 0.840 |
Why?
|
| Hyperthyroidism | 3 | 2022 | 294 | 0.820 |
Why?
|
| Adult | 192 | 2024 | 220969 | 0.810 |
Why?
|
| Dilatation and Curettage | 9 | 2012 | 52 | 0.770 |
Why?
|
| Adenocarcinoma, Clear Cell | 11 | 2020 | 217 | 0.770 |
Why?
|
| Peritoneal Neoplasms | 19 | 2020 | 710 | 0.710 |
Why?
|
| Endometrial Neoplasms | 14 | 2020 | 1365 | 0.700 |
Why?
|
| Cohort Studies | 30 | 2023 | 41457 | 0.670 |
Why?
|
| Remission Induction | 16 | 2020 | 2391 | 0.650 |
Why?
|
| Fallopian Tube Diseases | 2 | 2016 | 60 | 0.630 |
Why?
|
| Ovary | 16 | 2018 | 959 | 0.630 |
Why?
|
| Antineoplastic Agents | 30 | 2021 | 13635 | 0.630 |
Why?
|
| Young Adult | 34 | 2024 | 59179 | 0.620 |
Why?
|
| Uterine Cervical Neoplasms | 15 | 2021 | 2020 | 0.620 |
Why?
|
| Curettage | 3 | 2016 | 74 | 0.610 |
Why?
|
| Fallopian Tubes | 5 | 2018 | 178 | 0.600 |
Why?
|
| Cyclophosphamide | 15 | 2023 | 2218 | 0.590 |
Why?
|
| Vulvar Neoplasms | 7 | 2018 | 263 | 0.560 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2017 | 190 | 0.560 |
Why?
|
| Genital Neoplasms, Female | 6 | 2013 | 532 | 0.550 |
Why?
|
| Hypothyroidism | 1 | 2022 | 667 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 26 | 2020 | 8542 | 0.550 |
Why?
|
| Vincristine | 7 | 2023 | 1036 | 0.540 |
Why?
|
| Cysts | 1 | 2022 | 680 | 0.540 |
Why?
|
| CA-125 Antigen | 8 | 2020 | 276 | 0.540 |
Why?
|
| Hungary | 6 | 2016 | 82 | 0.540 |
Why?
|
| Cystadenocarcinoma, Papillary | 10 | 2012 | 56 | 0.530 |
Why?
|
| Drug Substitution | 1 | 2019 | 290 | 0.530 |
Why?
|
| Neoplasms, Multiple Primary | 6 | 2017 | 592 | 0.530 |
Why?
|
| Adolescent | 61 | 2021 | 88234 | 0.510 |
Why?
|
| Risk Factors | 56 | 2024 | 74115 | 0.500 |
Why?
|
| Prognosis | 57 | 2024 | 29600 | 0.480 |
Why?
|
| Carcinoma in Situ | 7 | 2018 | 791 | 0.470 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 4 | 2019 | 194 | 0.470 |
Why?
|
| Adenocarcinoma, Mucinous | 13 | 2020 | 517 | 0.470 |
Why?
|
| DNA, Neoplasm | 18 | 2017 | 1743 | 0.460 |
Why?
|
| Middle Aged | 140 | 2024 | 220584 | 0.460 |
Why?
|
| Matrix Metalloproteinases | 2 | 2011 | 391 | 0.450 |
Why?
|
| Carcinoma | 15 | 2019 | 2327 | 0.450 |
Why?
|
| Immunohistochemistry | 30 | 2018 | 11069 | 0.440 |
Why?
|
| South America | 3 | 2020 | 179 | 0.440 |
Why?
|
| Interferon Type I | 1 | 2017 | 557 | 0.420 |
Why?
|
| Sialoglycoproteins | 5 | 2006 | 315 | 0.420 |
Why?
|
| p21-Activated Kinases | 1 | 2013 | 127 | 0.420 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2011 | 97 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2013 | 140 | 0.410 |
Why?
|
| Endometriosis | 4 | 2016 | 857 | 0.390 |
Why?
|
| Loss of Heterozygosity | 15 | 2012 | 662 | 0.390 |
Why?
|
| Carboplatin | 10 | 2019 | 793 | 0.380 |
Why?
|
| Prenatal Diagnosis | 2 | 2018 | 1265 | 0.380 |
Why?
|
| Abortion, Induced | 1 | 2017 | 461 | 0.370 |
Why?
|
| Pre-Eclampsia | 4 | 2017 | 1230 | 0.360 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2004 | 1056 | 0.360 |
Why?
|
| Metrorrhagia | 1 | 2010 | 17 | 0.350 |
Why?
|
| Pregnancy, Multiple | 4 | 2017 | 215 | 0.340 |
Why?
|
| Neutrophils | 1 | 2022 | 3763 | 0.340 |
Why?
|
| Ovarian Cysts | 5 | 2020 | 108 | 0.330 |
Why?
|
| Stillbirth | 3 | 2021 | 368 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 3492 | 0.330 |
Why?
|
| Neoplasm, Residual | 6 | 2021 | 1008 | 0.320 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 664 | 0.310 |
Why?
|
| MicroRNAs | 7 | 2020 | 3805 | 0.310 |
Why?
|
| Fertility | 3 | 2010 | 769 | 0.310 |
Why?
|
| RNA, Neoplasm | 6 | 2020 | 749 | 0.300 |
Why?
|
| Treatment Outcome | 32 | 2022 | 64568 | 0.300 |
Why?
|
| Gravidity | 3 | 2021 | 50 | 0.300 |
Why?
|
| Combined Modality Therapy | 20 | 2016 | 8516 | 0.300 |
Why?
|
| Risk | 15 | 2022 | 9604 | 0.290 |
Why?
|
| Drug Administration Schedule | 10 | 2021 | 4845 | 0.280 |
Why?
|
| Disease Management | 4 | 2024 | 2506 | 0.280 |
Why?
|
| Gestational Age | 10 | 2021 | 3577 | 0.280 |
Why?
|
| Lung Neoplasms | 7 | 2021 | 13382 | 0.270 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2009 | 1754 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2021 | 3514 | 0.270 |
Why?
|
| Thoracotomy | 1 | 2008 | 366 | 0.270 |
Why?
|
| Antigens | 3 | 2008 | 1441 | 0.270 |
Why?
|
| Neoplasm Metastasis | 18 | 2014 | 4910 | 0.270 |
Why?
|
| Immunity, Cellular | 4 | 2010 | 1550 | 0.270 |
Why?
|
| Epithelial Cells | 12 | 2018 | 3672 | 0.270 |
Why?
|
| Isoenzymes | 4 | 2013 | 1687 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2018 | 2821 | 0.260 |
Why?
|
| Abortion, Spontaneous | 4 | 2021 | 532 | 0.260 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5430 | 0.250 |
Why?
|
| Papillomavirus Infections | 4 | 2021 | 1611 | 0.250 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2208 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 13 | 2015 | 3777 | 0.250 |
Why?
|
| Apoptosis | 7 | 2020 | 9476 | 0.250 |
Why?
|
| Adenocarcinoma | 12 | 2019 | 6340 | 0.240 |
Why?
|
| Cross-Sectional Studies | 9 | 2023 | 26049 | 0.240 |
Why?
|
| Chorionic Villi | 4 | 2017 | 53 | 0.240 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 799 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 20 | 2020 | 6126 | 0.240 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 3194 | 0.230 |
Why?
|
| Carcinosarcoma | 2 | 2015 | 106 | 0.230 |
Why?
|
| Alcohol Oxidoreductases | 2 | 2016 | 168 | 0.230 |
Why?
|
| Microvessels | 1 | 2008 | 577 | 0.230 |
Why?
|
| Chromosome Deletion | 7 | 2000 | 1386 | 0.230 |
Why?
|
| Cell Line, Tumor | 18 | 2018 | 16967 | 0.220 |
Why?
|
| Overweight | 1 | 2015 | 2417 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2019 | 4020 | 0.220 |
Why?
|
| Carcinoma, Papillary | 4 | 2013 | 785 | 0.220 |
Why?
|
| Cisplatin | 7 | 2016 | 1650 | 0.220 |
Why?
|
| Paget Disease, Extramammary | 2 | 2018 | 51 | 0.220 |
Why?
|
| Genes, p53 | 9 | 2010 | 712 | 0.220 |
Why?
|
| Cell Adhesion Molecules | 5 | 2016 | 1602 | 0.220 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 321 | 0.220 |
Why?
|
| RNA, Messenger | 23 | 2018 | 12758 | 0.220 |
Why?
|
| Cellular Structures | 1 | 2022 | 9 | 0.210 |
Why?
|
| Registries | 9 | 2024 | 8207 | 0.210 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2020 | 678 | 0.210 |
Why?
|
| North America | 2 | 2017 | 1273 | 0.210 |
Why?
|
| Paclitaxel | 10 | 2016 | 1730 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 19 | 2018 | 3593 | 0.210 |
Why?
|
| Ploidies | 6 | 2010 | 285 | 0.210 |
Why?
|
| Antigens, Neoplasm | 9 | 2013 | 1985 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3088 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 16 | 2016 | 4570 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3209 | 0.200 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2023 | 156 | 0.200 |
Why?
|
| Growth Substances | 1 | 2004 | 768 | 0.200 |
Why?
|
| Follow-Up Studies | 27 | 2020 | 39063 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 8 | 2021 | 2827 | 0.200 |
Why?
|
| Fertilization | 1 | 2023 | 198 | 0.200 |
Why?
|
| Aged | 77 | 2021 | 169042 | 0.200 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2014 | 276 | 0.200 |
Why?
|
| Papillomaviridae | 4 | 2019 | 1117 | 0.200 |
Why?
|
| Blood Cell Count | 1 | 2022 | 397 | 0.190 |
Why?
|
| Lutein | 1 | 2022 | 123 | 0.190 |
Why?
|
| Live Birth | 2 | 2017 | 510 | 0.190 |
Why?
|
| Neoplasm Proteins | 8 | 2006 | 3607 | 0.190 |
Why?
|
| Cervix Uteri | 3 | 2021 | 570 | 0.190 |
Why?
|
| Genes, ras | 6 | 2001 | 654 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 23 | 2017 | 6074 | 0.190 |
Why?
|
| Tumor Virus Infections | 2 | 2002 | 438 | 0.190 |
Why?
|
| Gynecology | 3 | 2016 | 526 | 0.190 |
Why?
|
| Genes, BRCA1 | 5 | 2013 | 753 | 0.190 |
Why?
|
| Telemedicine | 1 | 2018 | 3050 | 0.180 |
Why?
|
| Osteonectin | 2 | 2001 | 33 | 0.180 |
Why?
|
| HLA Antigens | 8 | 1986 | 1329 | 0.180 |
Why?
|
| Lymphocytes | 3 | 2022 | 2604 | 0.180 |
Why?
|
| Bleomycin | 4 | 2012 | 494 | 0.180 |
Why?
|
| Hysteroscopy | 1 | 2021 | 62 | 0.180 |
Why?
|
| Uterine Artery | 1 | 2020 | 30 | 0.180 |
Why?
|
| Uterus | 5 | 2012 | 649 | 0.180 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2020 | 27 | 0.180 |
Why?
|
| Disease-Free Survival | 12 | 2021 | 6807 | 0.170 |
Why?
|
| Semen | 1 | 2023 | 347 | 0.170 |
Why?
|
| Heat-Shock Proteins | 2 | 2004 | 795 | 0.170 |
Why?
|
| X-Rays | 1 | 2021 | 307 | 0.170 |
Why?
|
| Survival Rate | 13 | 2020 | 12719 | 0.170 |
Why?
|
| Aged, 80 and over | 34 | 2021 | 58894 | 0.170 |
Why?
|
| Community Health Centers | 1 | 2023 | 460 | 0.170 |
Why?
|
| Treatment Refusal | 1 | 2003 | 429 | 0.170 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 1998 | 304 | 0.170 |
Why?
|
| Arteriovenous Malformations | 1 | 2003 | 396 | 0.170 |
Why?
|
| Mixed Tumor, Mullerian | 3 | 2004 | 55 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 1169 | 0.170 |
Why?
|
| Iodide Peroxidase | 1 | 2021 | 294 | 0.170 |
Why?
|
| Vitamin A | 2 | 2020 | 612 | 0.170 |
Why?
|
| Genes, erbB-1 | 1 | 2000 | 162 | 0.170 |
Why?
|
| Cell Proliferation | 9 | 2020 | 10432 | 0.170 |
Why?
|
| Angiopoietin-2 | 2 | 2012 | 172 | 0.160 |
Why?
|
| Infusions, Intravenous | 4 | 2017 | 2214 | 0.160 |
Why?
|
| Immunotherapy | 4 | 2024 | 4642 | 0.160 |
Why?
|
| Gene Expression Profiling | 13 | 2017 | 9417 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 1999 | 151 | 0.160 |
Why?
|
| Fluorescent Antibody Technique | 12 | 2016 | 2467 | 0.160 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 3196 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2020 | 1404 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2008 | 2546 | 0.160 |
Why?
|
| Ostomy | 1 | 2019 | 33 | 0.160 |
Why?
|
| Cell Line | 13 | 2017 | 15576 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 350 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 2 | 2010 | 2644 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2018 | 2917 | 0.160 |
Why?
|
| Time Factors | 23 | 2020 | 39913 | 0.160 |
Why?
|
| Contraceptive Devices, Female | 2 | 2017 | 40 | 0.160 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1999 | 106 | 0.160 |
Why?
|
| BRCA1 Protein | 6 | 2013 | 1149 | 0.160 |
Why?
|
| Endometrium | 3 | 1994 | 403 | 0.160 |
Why?
|
| Predictive Value of Tests | 14 | 2017 | 15251 | 0.160 |
Why?
|
| Ovariectomy | 7 | 2013 | 613 | 0.150 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 3 | 1993 | 138 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 697 | 0.150 |
Why?
|
| Age Factors | 12 | 2016 | 18381 | 0.150 |
Why?
|
| Organoids | 2 | 2018 | 744 | 0.150 |
Why?
|
| Thyrotropin | 1 | 2022 | 834 | 0.150 |
Why?
|
| Pregnancy, Tubal | 1 | 1998 | 15 | 0.150 |
Why?
|
| Disease Progression | 7 | 2021 | 13495 | 0.150 |
Why?
|
| Medical Records | 6 | 2006 | 1407 | 0.150 |
Why?
|
| Diagnosis, Differential | 15 | 2020 | 12966 | 0.150 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 53 | 0.150 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
| Mullerian Ducts | 2 | 2016 | 203 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2017 | 245 | 0.150 |
Why?
|
| Folic Acid Antagonists | 1 | 1998 | 75 | 0.150 |
Why?
|
| Ascitic Fluid | 1 | 2018 | 189 | 0.150 |
Why?
|
| Precancerous Conditions | 4 | 2018 | 980 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 6 | 4 | 2001 | 367 | 0.140 |
Why?
|
| Killer Cells, Natural | 6 | 2022 | 2191 | 0.140 |
Why?
|
| Enterotoxins | 2 | 2010 | 366 | 0.140 |
Why?
|
| Endometrial Hyperplasia | 2 | 1995 | 97 | 0.140 |
Why?
|
| Brachytherapy | 3 | 2015 | 1223 | 0.140 |
Why?
|
| Cyclin A1 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 11 | 2017 | 9172 | 0.140 |
Why?
|
| Organoplatinum Compounds | 3 | 2013 | 407 | 0.140 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 5789 | 0.140 |
Why?
|
| DNA-Binding Proteins | 5 | 2016 | 9586 | 0.130 |
Why?
|
| Gene Expression | 9 | 2016 | 7568 | 0.130 |
Why?
|
| Sensitivity and Specificity | 11 | 2021 | 14648 | 0.130 |
Why?
|
| Serum | 1 | 2017 | 208 | 0.130 |
Why?
|
| Logistic Models | 5 | 2018 | 13245 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2016 | 1113 | 0.130 |
Why?
|
| Pulmonary Embolism | 3 | 2019 | 2568 | 0.130 |
Why?
|
| Ascites | 1 | 2018 | 338 | 0.130 |
Why?
|
| Obesity | 3 | 2015 | 12933 | 0.130 |
Why?
|
| Genetic Markers | 8 | 2020 | 2601 | 0.130 |
Why?
|
| Doxorubicin | 8 | 2020 | 2224 | 0.130 |
Why?
|
| Embolization, Therapeutic | 2 | 2003 | 1418 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 899 | 0.130 |
Why?
|
| Antibodies, Neoplasm | 2 | 2010 | 280 | 0.130 |
Why?
|
| Incidence | 9 | 2016 | 21337 | 0.130 |
Why?
|
| Cloning, Molecular | 3 | 1999 | 4172 | 0.130 |
Why?
|
| Remote Consultation | 1 | 2018 | 237 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1998 | 4512 | 0.120 |
Why?
|
| Case-Control Studies | 12 | 2020 | 22148 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2016 | 198 | 0.120 |
Why?
|
| Teratoma | 1 | 2018 | 404 | 0.120 |
Why?
|
| Multivariate Analysis | 8 | 2020 | 12043 | 0.120 |
Why?
|
| Contraceptives, Oral | 4 | 2009 | 553 | 0.120 |
Why?
|
| Fetal Death | 1 | 2017 | 435 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 1998 | 418 | 0.120 |
Why?
|
| Pregnancy Trimester, First | 4 | 2000 | 908 | 0.120 |
Why?
|
| Parity | 5 | 2016 | 924 | 0.120 |
Why?
|
| RNA Precursors | 1 | 2016 | 200 | 0.120 |
Why?
|
| Sexual Partners | 1 | 1999 | 800 | 0.120 |
Why?
|
| Brain Neoplasms | 8 | 2024 | 9026 | 0.120 |
Why?
|
| Referral and Consultation | 4 | 2021 | 3599 | 0.120 |
Why?
|
| Ribonuclease III | 1 | 2016 | 279 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 4 | 2008 | 1051 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3634 | 0.110 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2013 | 42 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2008 | 10175 | 0.110 |
Why?
|
| DNA, Complementary | 7 | 2005 | 1989 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 568 | 0.110 |
Why?
|
| Laparoscopy | 6 | 2015 | 2030 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2016 | 731 | 0.110 |
Why?
|
| Colectomy | 1 | 2019 | 686 | 0.110 |
Why?
|
| Obstetrics | 2 | 2016 | 666 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6474 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2016 | 384 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1995 | 340 | 0.110 |
Why?
|
| Antigen-Antibody Complex | 6 | 1986 | 509 | 0.110 |
Why?
|
| DNA Helicases | 1 | 1999 | 851 | 0.110 |
Why?
|
| World Health Organization | 2 | 2016 | 1321 | 0.110 |
Why?
|
| Hospitals, Special | 1 | 2013 | 91 | 0.100 |
Why?
|
| Adenine Nucleotide Translocator 2 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Chromosomes, Human | 1 | 1995 | 441 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 380 | 0.100 |
Why?
|
| Hydrops Fetalis | 1 | 2013 | 113 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2006 | 563 | 0.100 |
Why?
|
| Term Birth | 1 | 2013 | 138 | 0.100 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 12447 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2021 | 3800 | 0.100 |
Why?
|
| Antioxidants | 1 | 2020 | 1668 | 0.100 |
Why?
|
| Cell Death | 2 | 2015 | 1677 | 0.100 |
Why?
|
| Sphingolipids | 1 | 2013 | 173 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2019 | 2195 | 0.100 |
Why?
|
| Pelvic Neoplasms | 2 | 2020 | 247 | 0.100 |
Why?
|
| Diseases in Twins | 1 | 1994 | 446 | 0.100 |
Why?
|
| Osteopontin | 5 | 2006 | 301 | 0.100 |
Why?
|
| Vitamins | 1 | 2020 | 1635 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 4408 | 0.100 |
Why?
|
| Gene Deletion | 7 | 2004 | 2661 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 146 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2012 | 119 | 0.100 |
Why?
|
| Angiopoietin-1 | 1 | 2012 | 122 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2018 | 1565 | 0.100 |
Why?
|
| In Situ Hybridization | 3 | 2010 | 1900 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2008 | 1779 | 0.090 |
Why?
|
| Clostridium perfringens | 2 | 2010 | 29 | 0.090 |
Why?
|
| Massachusetts | 5 | 2018 | 8833 | 0.090 |
Why?
|
| Pandemics | 2 | 2022 | 8645 | 0.090 |
Why?
|
| Cadherins | 1 | 2016 | 901 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 222 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2007 | 386 | 0.090 |
Why?
|
| Cell Division | 9 | 2001 | 4457 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2016 | 1329 | 0.090 |
Why?
|
| Molecular Sequence Data | 13 | 2006 | 17629 | 0.090 |
Why?
|
| Epithelium | 7 | 2008 | 1603 | 0.090 |
Why?
|
| Alleles | 13 | 2005 | 6861 | 0.090 |
Why?
|
| Colposcopy | 2 | 2021 | 149 | 0.090 |
Why?
|
| Postpartum Period | 1 | 1998 | 1178 | 0.090 |
Why?
|
| Versicans | 1 | 2010 | 40 | 0.090 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 6 | 2001 | 329 | 0.090 |
Why?
|
| Cystadenocarcinoma | 5 | 1994 | 54 | 0.090 |
Why?
|
| New Hampshire | 1 | 2010 | 175 | 0.090 |
Why?
|
| Genes, BRCA2 | 1 | 2013 | 590 | 0.090 |
Why?
|
| Survivors | 3 | 2007 | 2372 | 0.090 |
Why?
|
| Cell Count | 2 | 2010 | 1835 | 0.090 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2011 | 110 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2018 | 2764 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2018 | 2554 | 0.080 |
Why?
|
| Mutation | 16 | 2018 | 30016 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1992 | 1349 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 1529 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 20556 | 0.080 |
Why?
|
| Menopause | 2 | 1994 | 1645 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 1088 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2016 | 1299 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 546 | 0.080 |
Why?
|
| Biological Factors | 1 | 1990 | 157 | 0.080 |
Why?
|
| DNA Repair | 1 | 2018 | 2043 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2020 | 3113 | 0.080 |
Why?
|
| Recurrence | 7 | 2019 | 8426 | 0.080 |
Why?
|
| Gene Dosage | 3 | 2016 | 1217 | 0.080 |
Why?
|
| Appendiceal Neoplasms | 2 | 2005 | 155 | 0.080 |
Why?
|
| Germ-Line Mutation | 3 | 2013 | 1852 | 0.080 |
Why?
|
| Cytokines | 5 | 1998 | 7373 | 0.080 |
Why?
|
| Anesthetics | 1 | 2014 | 523 | 0.080 |
Why?
|
| Gene Amplification | 5 | 2007 | 1087 | 0.080 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 117 | 0.080 |
Why?
|
| Granulosa Cell Tumor | 1 | 2009 | 77 | 0.080 |
Why?
|
| Contractile Proteins | 1 | 2009 | 240 | 0.080 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 129 | 0.080 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 57 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.080 |
Why?
|
| Infusions, Parenteral | 2 | 2021 | 397 | 0.080 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 384 | 0.080 |
Why?
|
| Karyotyping | 5 | 1995 | 1171 | 0.080 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 615 | 0.080 |
Why?
|
| Fetal Diseases | 1 | 1994 | 913 | 0.080 |
Why?
|
| Tight Junctions | 2 | 2010 | 324 | 0.080 |
Why?
|
| Child | 7 | 2018 | 80079 | 0.080 |
Why?
|
| Autoantibodies | 2 | 2010 | 2115 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2007 | 1301 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 2756 | 0.080 |
Why?
|
| Genomic Instability | 1 | 2012 | 709 | 0.080 |
Why?
|
| Ultrasonography | 6 | 1997 | 5964 | 0.070 |
Why?
|
| Embryo Implantation | 2 | 1996 | 270 | 0.070 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1990 | 491 | 0.070 |
Why?
|
| Cell Movement | 3 | 2016 | 5200 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2012 | 743 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 2864 | 0.070 |
Why?
|
| Transfection | 5 | 2015 | 5766 | 0.070 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2007 | 56 | 0.070 |
Why?
|
| Lymphokines | 2 | 1988 | 925 | 0.070 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1988 | 508 | 0.070 |
Why?
|
| Salmon | 1 | 2007 | 34 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 5 | 2001 | 1703 | 0.070 |
Why?
|
| Proteins | 3 | 1999 | 6030 | 0.070 |
Why?
|
| Talc | 1 | 2007 | 48 | 0.070 |
Why?
|
| Postmenopause | 2 | 2004 | 2511 | 0.070 |
Why?
|
| Up-Regulation | 8 | 2010 | 4117 | 0.070 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 796 | 0.070 |
Why?
|
| Dissection | 3 | 2003 | 297 | 0.070 |
Why?
|
| Risk Assessment | 7 | 2021 | 23972 | 0.070 |
Why?
|
| Hydatidiform Mole, Invasive | 3 | 1998 | 4 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2018 | 878 | 0.070 |
Why?
|
| X Chromosome | 4 | 1998 | 816 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2016 | 1134 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2014 | 1606 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1937 | 0.070 |
Why?
|
| Selenium-Binding Proteins | 1 | 2006 | 18 | 0.070 |
Why?
|
| Base Sequence | 9 | 2000 | 12421 | 0.070 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 2006 | 13 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2022 | 54360 | 0.070 |
Why?
|
| Myometrium | 1 | 2007 | 174 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 1986 | 860 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 974 | 0.070 |
Why?
|
| Decidua | 2 | 2022 | 82 | 0.070 |
Why?
|
| Radioimmunoassay | 6 | 1994 | 861 | 0.070 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 4110 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2000 | 2747 | 0.070 |
Why?
|
| Hong Kong | 2 | 2017 | 163 | 0.070 |
Why?
|
| Granzymes | 1 | 2007 | 277 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2022 | 26180 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2003 | 2915 | 0.060 |
Why?
|
| United States | 6 | 2021 | 72272 | 0.060 |
Why?
|
| Heterozygote | 6 | 2005 | 2780 | 0.060 |
Why?
|
| Cell Survival | 6 | 2016 | 5780 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 2 | 2012 | 1350 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1992 | 1835 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2018 | 2495 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 1866 | 0.060 |
Why?
|
| Lymph Nodes | 4 | 2007 | 3461 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2020 | 7847 | 0.060 |
Why?
|
| Cytoplasm | 4 | 2008 | 1503 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2010 | 2241 | 0.060 |
Why?
|
| Lasers | 3 | 2004 | 952 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 1997 | 310 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 1784 | 0.060 |
Why?
|
| Immune Sera | 2 | 1983 | 605 | 0.060 |
Why?
|
| Histocompatibility Antigens | 1 | 1986 | 464 | 0.060 |
Why?
|
| Signal Transduction | 5 | 2015 | 23416 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2006 | 2801 | 0.060 |
Why?
|
| Cystadenocarcinoma, Mucinous | 2 | 2005 | 50 | 0.060 |
Why?
|
| Peptide Fragments | 6 | 2007 | 5110 | 0.060 |
Why?
|
| Premature Birth | 1 | 2017 | 1782 | 0.060 |
Why?
|
| BRCA2 Protein | 2 | 2007 | 797 | 0.060 |
Why?
|
| Mucin-1 | 2 | 2009 | 538 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 1996 | 322 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2021 | 5239 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2008 | 3077 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 550 | 0.060 |
Why?
|
| Vagina | 3 | 2015 | 841 | 0.060 |
Why?
|
| Co-Repressor Proteins | 2 | 2016 | 189 | 0.060 |
Why?
|
| Glycolipids | 1 | 1985 | 206 | 0.060 |
Why?
|
| Pregnadienediols | 1 | 2003 | 9 | 0.060 |
Why?
|
| Blotting, Northern | 3 | 1994 | 1545 | 0.060 |
Why?
|
| Amino Acid Sequence | 6 | 2006 | 13441 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1263 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 11874 | 0.060 |
Why?
|
| Body Mass Index | 4 | 2016 | 12943 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2007 | 571 | 0.060 |
Why?
|
| Cell Adhesion | 3 | 2016 | 3088 | 0.050 |
Why?
|
| Anemia | 2 | 2012 | 1504 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2048 | 0.050 |
Why?
|
| Developing Countries | 1 | 2016 | 2867 | 0.050 |
Why?
|
| Quality of Life | 6 | 2005 | 13347 | 0.050 |
Why?
|
| Cyclin E | 1 | 2004 | 155 | 0.050 |
Why?
|
| Population Surveillance | 1 | 1994 | 2595 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2005 | 629 | 0.050 |
Why?
|
| Y Chromosome | 2 | 1995 | 205 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 619 | 0.050 |
Why?
|
| Micromanipulation | 1 | 2003 | 53 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 915 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 1790 | 0.050 |
Why?
|
| Kallikreins | 1 | 2004 | 220 | 0.050 |
Why?
|
| Intraoperative Complications | 3 | 2007 | 1161 | 0.050 |
Why?
|
| Marriage | 4 | 2003 | 349 | 0.050 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 1269 | 0.050 |
Why?
|
| Mass Screening | 2 | 2001 | 5424 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2005 | 685 | 0.050 |
Why?
|
| Family Therapy | 5 | 1990 | 215 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3599 | 0.050 |
Why?
|
| Transcription Factors | 5 | 2002 | 12116 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2016 | 3742 | 0.050 |
Why?
|
| Microsatellite Repeats | 6 | 2001 | 783 | 0.050 |
Why?
|
| Abortion, Missed | 3 | 1994 | 12 | 0.050 |
Why?
|
| Budesonide | 1 | 2003 | 157 | 0.050 |
Why?
|
| Point Mutation | 2 | 2000 | 1595 | 0.050 |
Why?
|
| Lymphatic Metastasis | 5 | 2015 | 2913 | 0.050 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2002 | 99 | 0.050 |
Why?
|
| Haptoglobins | 1 | 2003 | 165 | 0.050 |
Why?
|
| Survival Analysis | 7 | 2012 | 10073 | 0.050 |
Why?
|
| Propionibacterium acnes | 2 | 1983 | 59 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3206 | 0.050 |
Why?
|
| Leukocytes | 1 | 1990 | 2023 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2009 | 2200 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2013 | 3998 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2015 | 3442 | 0.050 |
Why?
|
| Cholecalciferol | 1 | 2007 | 553 | 0.050 |
Why?
|
| DNA Methylation | 4 | 2017 | 4391 | 0.050 |
Why?
|
| Polyploidy | 1 | 2002 | 119 | 0.050 |
Why?
|
| Dissociative Disorders | 2 | 1994 | 233 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2009 | 4341 | 0.050 |
Why?
|
| Animals | 19 | 2022 | 168201 | 0.050 |
Why?
|
| Piperazines | 2 | 2013 | 2521 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2014 | 11514 | 0.050 |
Why?
|
| Blotting, Western | 5 | 2010 | 5034 | 0.050 |
Why?
|
| Spermatozoa | 1 | 1985 | 629 | 0.050 |
Why?
|
| Turner Syndrome | 1 | 1982 | 128 | 0.050 |
Why?
|
| CHO Cells | 2 | 2010 | 1387 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 1988 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2013 | 2317 | 0.050 |
Why?
|
| Flow Cytometry | 6 | 2010 | 5863 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2000 | 228 | 0.050 |
Why?
|
| Genital Diseases, Female | 2 | 2001 | 192 | 0.050 |
Why?
|
| Cystadenoma | 2 | 2000 | 79 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 774 | 0.050 |
Why?
|
| Abortion, Incomplete | 2 | 1994 | 14 | 0.050 |
Why?
|
| Puerperal Disorders | 1 | 1984 | 300 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 4571 | 0.050 |
Why?
|
| Estradiol | 5 | 1994 | 1937 | 0.050 |
Why?
|
| Infant | 1 | 2023 | 36152 | 0.040 |
Why?
|
| Mice | 12 | 2022 | 81368 | 0.040 |
Why?
|
| Liver Neoplasms | 3 | 2011 | 4308 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2002 | 251 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2020 | 148 | 0.040 |
Why?
|
| Psychotherapy, Group | 3 | 1990 | 413 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1614 | 0.040 |
Why?
|
| Protein Biosynthesis | 4 | 2006 | 2100 | 0.040 |
Why?
|
| Human Genome Project | 1 | 2000 | 200 | 0.040 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 1999 | 20 | 0.040 |
Why?
|
| Electrocoagulation | 1 | 2020 | 152 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 3794 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 5780 | 0.040 |
Why?
|
| Selenoproteins | 1 | 2021 | 215 | 0.040 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
| Cardiac Output, Low | 1 | 2000 | 191 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2007 | 5463 | 0.040 |
Why?
|
| Indoles | 1 | 2007 | 1830 | 0.040 |
Why?
|
| Observer Variation | 3 | 2019 | 2606 | 0.040 |
Why?
|
| Cells, Cultured | 8 | 2010 | 18937 | 0.040 |
Why?
|
| Receptor, erbB-3 | 1 | 2000 | 143 | 0.040 |
Why?
|
| Information Services | 1 | 2000 | 236 | 0.040 |
Why?
|
| Cytogenetics | 2 | 1992 | 198 | 0.040 |
Why?
|
| Suction | 1 | 2020 | 266 | 0.040 |
Why?
|
| RecQ Helicases | 1 | 1999 | 53 | 0.040 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2019 | 109 | 0.040 |
Why?
|
| Topotecan | 3 | 2004 | 131 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1608 | 0.040 |
Why?
|
| RNA, Untranslated | 1 | 2002 | 456 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2010 | 384 | 0.040 |
Why?
|
| Infertility, Female | 1 | 2005 | 760 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2009 | 7389 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2013 | 3269 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 1993 | 3145 | 0.040 |
Why?
|
| Uterine Perforation | 1 | 2018 | 4 | 0.040 |
Why?
|
| Chickens | 1 | 2020 | 858 | 0.040 |
Why?
|
| Biological Products | 1 | 1988 | 912 | 0.040 |
Why?
|
| Omentum | 1 | 2019 | 167 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2003 | 574 | 0.040 |
Why?
|
| Online Systems | 1 | 2019 | 182 | 0.040 |
Why?
|
| Human papillomavirus 18 | 1 | 2019 | 125 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 561 | 0.040 |
Why?
|
| Genetic Complementation Test | 1 | 1999 | 555 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2006 | 506 | 0.040 |
Why?
|
| Carotenoids | 2 | 1995 | 621 | 0.040 |
Why?
|
| Cytarabine | 1 | 2020 | 697 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 5332 | 0.040 |
Why?
|
| Spinal Puncture | 1 | 2000 | 282 | 0.040 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1998 | 94 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2007 | 2629 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2012 | 3605 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1977 | 0.040 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 1745 | 0.040 |
Why?
|
| RNA Interference | 2 | 2017 | 2830 | 0.040 |
Why?
|
| Male | 24 | 2023 | 360358 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 1302 | 0.040 |
Why?
|
| Drug Therapy, Combination | 6 | 1984 | 6305 | 0.040 |
Why?
|
| Genome | 1 | 2005 | 1737 | 0.040 |
Why?
|
| Radiography | 2 | 2007 | 6961 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2002 | 620 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2006 | 9643 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1997 | 783 | 0.040 |
Why?
|
| Saudi Arabia | 1 | 1998 | 210 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2003 | 786 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 1978 | 104 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2002 | 802 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 6925 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 267 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 2013 | 1865 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2000 | 632 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1998 | 360 | 0.030 |
Why?
|
| Contraception | 2 | 1995 | 347 | 0.030 |
Why?
|
| Fenfluramine | 1 | 1996 | 58 | 0.030 |
Why?
|
| Patient Compliance | 3 | 2004 | 2688 | 0.030 |
Why?
|
| Phenotype | 4 | 2018 | 16571 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2017 | 1964 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2020 | 1635 | 0.030 |
Why?
|
| Vulva | 2 | 2008 | 84 | 0.030 |
Why?
|
| Postpartum Hemorrhage | 1 | 1980 | 272 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 1022 | 0.030 |
Why?
|
| Postoperative Complications | 5 | 2021 | 15612 | 0.030 |
Why?
|
| Diet | 3 | 2007 | 8048 | 0.030 |
Why?
|
| Appetite Depressants | 1 | 1996 | 108 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 794 | 0.030 |
Why?
|
| Dietary Proteins | 2 | 1995 | 951 | 0.030 |
Why?
|
| Exons | 3 | 2000 | 2381 | 0.030 |
Why?
|
| Cell Line, Transformed | 2 | 2013 | 866 | 0.030 |
Why?
|
| DNA Probes | 3 | 2010 | 541 | 0.030 |
Why?
|
| Twins | 2 | 1995 | 340 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1997 | 410 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2019 | 464 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2010 | 613 | 0.030 |
Why?
|
| Pelvis | 1 | 1980 | 732 | 0.030 |
Why?
|
| Cyclins | 1 | 1998 | 594 | 0.030 |
Why?
|
| Histones | 1 | 2006 | 2577 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 17878 | 0.030 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 2020 | 0.030 |
Why?
|
| Lymphoma | 1 | 2005 | 1899 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 123 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1998 | 368 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1985 | 2802 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 3705 | 0.030 |
Why?
|
| Robotics | 2 | 2015 | 816 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 1662 | 0.030 |
Why?
|
| Transglutaminases | 1 | 2016 | 196 | 0.030 |
Why?
|
| Demography | 1 | 2020 | 1643 | 0.030 |
Why?
|
| Receptors, Androgen | 2 | 1998 | 1079 | 0.030 |
Why?
|
| Centromere | 1 | 1996 | 212 | 0.030 |
Why?
|
| Glycosylation | 2 | 2010 | 1098 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1999 | 2261 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1999 | 1230 | 0.030 |
Why?
|
| Etanidazole | 1 | 1994 | 22 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2013 | 2930 | 0.030 |
Why?
|
| Sexual Behavior | 4 | 2005 | 2187 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2021 | 3087 | 0.030 |
Why?
|
| Intermediate Filaments | 1 | 1995 | 171 | 0.030 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 1994 | 21 | 0.030 |
Why?
|
| Abortion, Therapeutic | 1 | 1994 | 35 | 0.030 |
Why?
|
| Thecoma | 1 | 1994 | 11 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 1985 | 813 | 0.030 |
Why?
|
| Menstruation Disturbances | 1 | 1995 | 143 | 0.030 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 1994 | 14 | 0.030 |
Why?
|
| Jews | 1 | 1996 | 356 | 0.030 |
Why?
|
| Lactosylceramides | 1 | 2013 | 15 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 1998 | 671 | 0.030 |
Why?
|
| Bulimia | 1 | 1996 | 400 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 1996 | 392 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2002 | 4010 | 0.030 |
Why?
|
| Length of Stay | 2 | 2021 | 6418 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1994 | 135 | 0.030 |
Why?
|
| Triage | 1 | 2021 | 983 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1995 | 375 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1755 | 0.030 |
Why?
|
| DNA Fingerprinting | 1 | 1994 | 114 | 0.030 |
Why?
|
| Agranulocytosis | 2 | 1984 | 97 | 0.030 |
Why?
|
| Taxoids | 2 | 2012 | 667 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 1810 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1994 | 155 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 526 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 1866 | 0.030 |
Why?
|
| Blotting, Southern | 3 | 2004 | 777 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 535 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1997 | 1031 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1978 | 1624 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1992 | 42 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1995 | 457 | 0.030 |
Why?
|
| Polymorphism, Genetic | 3 | 2002 | 4242 | 0.030 |
Why?
|
| Genes, myc | 1 | 1994 | 390 | 0.030 |
Why?
|
| Social Support | 4 | 2005 | 2174 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1994 | 393 | 0.030 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 2 | 1989 | 95 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1995 | 638 | 0.030 |
Why?
|
| Pyrazines | 1 | 2018 | 1202 | 0.030 |
Why?
|
| Clinical Enzyme Tests | 1 | 2012 | 113 | 0.030 |
Why?
|
| Family Health | 2 | 2009 | 1253 | 0.030 |
Why?
|
| Caffeine | 1 | 1997 | 699 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2007 | 6338 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1998 | 988 | 0.030 |
Why?
|
| Chromosome Mapping | 5 | 2000 | 4611 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1994 | 309 | 0.030 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 123 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 949 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 1998 | 2925 | 0.020 |
Why?
|
| Proteomics | 2 | 2022 | 3836 | 0.020 |
Why?
|
| Progesterone | 2 | 1994 | 742 | 0.020 |
Why?
|
| Biopsy | 3 | 2008 | 6762 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 737 | 0.020 |
Why?
|
| Transcription, Genetic | 4 | 2004 | 7583 | 0.020 |
Why?
|
| Cricetinae | 2 | 2010 | 2424 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2016 | 1642 | 0.020 |
Why?
|
| DNA Replication | 1 | 2018 | 1414 | 0.020 |
Why?
|
| Somatoform Disorders | 1 | 1994 | 423 | 0.020 |
Why?
|
| Dosage Compensation, Genetic | 3 | 1998 | 207 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 767 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2013 | 358 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 426 | 0.020 |
Why?
|
| DNA Damage | 2 | 2012 | 2446 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 1994 | 390 | 0.020 |
Why?
|
| Specialization | 1 | 2016 | 778 | 0.020 |
Why?
|
| Receptor, erbB-2 | 2 | 2001 | 2553 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1892 | 0.020 |
Why?
|
| Codon | 1 | 1993 | 600 | 0.020 |
Why?
|
| Genotype | 1 | 2005 | 12978 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2019 | 1037 | 0.020 |
Why?
|
| Schizophrenia | 5 | 1990 | 6929 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 1998 | 2895 | 0.020 |
Why?
|
| Splenectomy | 1 | 1992 | 389 | 0.020 |
Why?
|
| Fluoxetine | 1 | 1994 | 733 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1088 | 0.020 |
Why?
|
| Stress, Psychological | 5 | 2004 | 4488 | 0.020 |
Why?
|
| Neoplasms | 3 | 2015 | 22131 | 0.020 |
Why?
|
| Methionine | 1 | 2013 | 572 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6483 | 0.020 |
Why?
|
| Personality Inventory | 3 | 2005 | 1018 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 329 | 0.020 |
Why?
|
| Phthalazines | 1 | 2013 | 383 | 0.020 |
Why?
|
| Immune Tolerance | 2 | 1992 | 2299 | 0.020 |
Why?
|
| Thrombocytopenia | 3 | 2000 | 1182 | 0.020 |
Why?
|
| Triplets | 1 | 1990 | 42 | 0.020 |
Why?
|
| Home Nursing | 1 | 1990 | 92 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 3730 | 0.020 |
Why?
|
| Office Visits | 1 | 1994 | 593 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 1995 | 1202 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 687 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 1993 | 539 | 0.020 |
Why?
|
| Vaccination | 1 | 2002 | 3370 | 0.020 |
Why?
|
| Intestines | 1 | 2019 | 1909 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2010 | 170 | 0.020 |
Why?
|
| Viral Load | 1 | 2019 | 3325 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 270 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 277 | 0.020 |
Why?
|
| Gravitation | 1 | 2009 | 82 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 1836 | 0.020 |
Why?
|
| Estrogens | 3 | 2002 | 1521 | 0.020 |
Why?
|
| Melanoma | 1 | 2008 | 5697 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 2872 | 0.020 |
Why?
|
| Antibody Formation | 2 | 1984 | 1390 | 0.020 |
Why?
|
| Reference Values | 2 | 2000 | 4919 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 2639 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 814 | 0.020 |
Why?
|
| Obstetric Labor, Premature | 1 | 1990 | 272 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1998 | 3680 | 0.020 |
Why?
|
| Monokines | 1 | 1988 | 71 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18221 | 0.020 |
Why?
|
| Folic Acid | 1 | 2015 | 1323 | 0.020 |
Why?
|
| Receptors, Laminin | 1 | 2007 | 26 | 0.020 |
Why?
|
| Concanavalin A | 1 | 1988 | 190 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2674 | 0.020 |
Why?
|
| Fee-for-Service Plans | 1 | 2013 | 697 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2018 | 2008 | 0.020 |
Why?
|
| Electron Probe Microanalysis | 1 | 2007 | 32 | 0.020 |
Why?
|
| Somatomedins | 1 | 1988 | 179 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2008 | 730 | 0.020 |
Why?
|
| Aftercare | 1 | 1994 | 913 | 0.020 |
Why?
|
| Clinical Trials as Topic | 4 | 2000 | 7995 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 6520 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1988 | 218 | 0.020 |
Why?
|
| Abdomen | 1 | 2013 | 1128 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2446 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1995 | 1963 | 0.020 |
Why?
|
| Microscopy, Polarization | 1 | 2007 | 88 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 695 | 0.020 |
Why?
|
| Vinblastine | 2 | 1989 | 488 | 0.020 |
Why?
|
| Life Change Events | 4 | 1994 | 952 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2006 | 27 | 0.020 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2007 | 191 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2001 | 1813 | 0.020 |
Why?
|
| Sarcoma | 1 | 1978 | 1800 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 469 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 1663 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 2897 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 2 | 1983 | 91 | 0.020 |
Why?
|
| Emotions | 4 | 2003 | 2740 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3797 | 0.020 |
Why?
|
| Family | 3 | 1990 | 3193 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1992 | 1409 | 0.020 |
Why?
|
| Research Design | 1 | 2022 | 6174 | 0.020 |
Why?
|
| Proteome | 2 | 2006 | 1857 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 1540 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1988 | 816 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 283 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2137 | 0.020 |
Why?
|
| Autophagy | 1 | 2013 | 1326 | 0.020 |
Why?
|
| Corynebacterium | 1 | 1985 | 48 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 10754 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 1985 | 302 | 0.020 |
Why?
|
| Schizophrenic Psychology | 2 | 1990 | 1646 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 2625 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2007 | 304 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 944 | 0.020 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2005 | 7 | 0.020 |
Why?
|
| Binding Sites, Antibody | 1 | 1985 | 337 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 2007 | 370 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1185 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1994 | 1230 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 4947 | 0.020 |
Why?
|
| Infant Mortality | 1 | 1990 | 751 | 0.020 |
Why?
|
| Amniocentesis | 1 | 1985 | 115 | 0.020 |
Why?
|
| Filgrastim | 1 | 2005 | 132 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 319 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 656 | 0.010 |
Why?
|
| Groin | 1 | 1985 | 106 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 20074 | 0.010 |
Why?
|
| Microdissection | 1 | 2004 | 151 | 0.010 |
Why?
|
| Asthma | 1 | 2003 | 6233 | 0.010 |
Why?
|
| Breast Neoplasms | 4 | 2007 | 20988 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2009 | 727 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2013 | 4269 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 1320 | 0.010 |
Why?
|
| HLA-C Antigens | 1 | 1984 | 140 | 0.010 |
Why?
|
| Microvilli | 1 | 1984 | 234 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 1984 | 223 | 0.010 |
Why?
|
| Interferons | 1 | 1988 | 703 | 0.010 |
Why?
|
| Decision Trees | 1 | 2006 | 504 | 0.010 |
Why?
|
| Liver | 3 | 1990 | 7512 | 0.010 |
Why?
|
| Drug Costs | 1 | 2012 | 1183 | 0.010 |
Why?
|
| Sequence Deletion | 2 | 2000 | 1490 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1988 | 1146 | 0.010 |
Why?
|
| Data Collection | 1 | 2013 | 3315 | 0.010 |
Why?
|
| Neutropenia | 2 | 2000 | 885 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1985 | 696 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2005 | 451 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2008 | 1081 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 629 | 0.010 |
Why?
|
| Boston | 3 | 2005 | 9313 | 0.010 |
Why?
|
| Double-Blind Method | 4 | 2003 | 12334 | 0.010 |
Why?
|
| Gonadotropins | 2 | 1982 | 241 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2002 | 2509 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 1985 | 291 | 0.010 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 1187 | 0.010 |
Why?
|
| Selenium | 1 | 2006 | 417 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1984 | 641 | 0.010 |
Why?
|
| Ovarian Diseases | 1 | 2004 | 136 | 0.010 |
Why?
|
| HLA-B Antigens | 1 | 1984 | 317 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 1993 | 1998 | 0.010 |
Why?
|
| Attitude to Health | 3 | 2003 | 2024 | 0.010 |
Why?
|
| Interleukins | 1 | 1988 | 783 | 0.010 |
Why?
|
| Reproduction | 2 | 2005 | 645 | 0.010 |
Why?
|
| Macrophages | 1 | 1998 | 5758 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 2005 | 428 | 0.010 |
Why?
|
| Chromosome Painting | 1 | 2002 | 26 | 0.010 |
Why?
|
| Transplantation, Homologous | 2 | 1984 | 4804 | 0.010 |
Why?
|
| Sexuality | 1 | 2004 | 180 | 0.010 |
Why?
|
| Genomic Imprinting | 1 | 2004 | 329 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2005 | 566 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 1650 | 0.010 |
Why?
|
| Biotin | 1 | 2003 | 252 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1995 | 4935 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 1994 | 4575 | 0.010 |
Why?
|
| Peritoneum | 2 | 1998 | 225 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2008 | 1503 | 0.010 |
Why?
|
| Genome, Human | 2 | 2005 | 4421 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2002 | 194 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1984 | 403 | 0.010 |
Why?
|
| Dimerization | 1 | 2003 | 890 | 0.010 |
Why?
|
| Child Abuse, Sexual | 2 | 1994 | 403 | 0.010 |
Why?
|
| Mitochondria | 1 | 2015 | 3619 | 0.010 |
Why?
|
| Age Distribution | 1 | 2007 | 2871 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 465 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 10548 | 0.010 |
Why?
|
| Polyadenylation | 1 | 2002 | 115 | 0.010 |
Why?
|
| Placebos | 2 | 1996 | 1667 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1983 | 1058 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2003 | 399 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1985 | 1605 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2016 | 14389 | 0.010 |
Why?
|
| Hyperemesis Gravidarum | 1 | 1981 | 23 | 0.010 |
Why?
|
| Child Abuse | 3 | 1994 | 1076 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2014 | 3548 | 0.010 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 1110 | 0.010 |
Why?
|
| Smoking | 2 | 2010 | 9050 | 0.010 |
Why?
|
| Complement C3 | 1 | 1982 | 434 | 0.010 |
Why?
|
| Pregnancy Complications | 2 | 1987 | 2948 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1988 | 1932 | 0.010 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 1980 | 55 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 1884 | 0.010 |
Why?
|
| Hospitalization | 3 | 1998 | 10704 | 0.010 |
Why?
|
| Contraceptive Agents, Female | 1 | 1981 | 118 | 0.010 |
Why?
|
| Psychology | 1 | 2002 | 356 | 0.010 |
Why?
|
| Computer Systems | 1 | 2001 | 469 | 0.010 |
Why?
|
| Vaginal Diseases | 1 | 1981 | 103 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9345 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 1994 | 6016 | 0.010 |
Why?
|
| Femoral Vein | 1 | 2000 | 153 | 0.010 |
Why?
|
| Spirituality | 1 | 2004 | 425 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 3419 | 0.010 |
Why?
|
| WT1 Proteins | 1 | 2000 | 184 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2006 | 2700 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 1415 | 0.010 |
Why?
|
| Palliative Care | 1 | 1994 | 3592 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 1998 | 92 | 0.010 |
Why?
|
| Iliac Artery | 1 | 1980 | 343 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1979 | 573 | 0.010 |
Why?
|
| Androgens | 1 | 2006 | 1285 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 1683 | 0.010 |
Why?
|
| Immunity | 1 | 1984 | 994 | 0.010 |
Why?
|
| Vasculitis | 1 | 1982 | 522 | 0.010 |
Why?
|
| Kinetics | 2 | 2001 | 6370 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2000 | 379 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2003 | 1814 | 0.010 |
Why?
|
| Mesna | 1 | 1998 | 62 | 0.010 |
Why?
|
| Estrone | 1 | 1979 | 234 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 1994 | 15828 | 0.010 |
Why?
|
| Physicians | 1 | 2016 | 4583 | 0.010 |
Why?
|
| Systole | 1 | 2000 | 935 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1982 | 1526 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1985 | 1995 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1998 | 232 | 0.010 |
Why?
|
| Epitopes | 1 | 1984 | 2501 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1997 | 66 | 0.010 |
Why?
|
| Neurofibromin 1 | 1 | 1999 | 190 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 784 | 0.010 |
Why?
|
| Trinucleotide Repeats | 1 | 1998 | 257 | 0.010 |
Why?
|
| Counseling | 1 | 2005 | 1538 | 0.010 |
Why?
|
| Rabbits | 1 | 1983 | 4770 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1977 | 645 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 1979 | 499 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 888 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1980 | 447 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5319 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1988 | 3309 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1977 | 913 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 2189 | 0.010 |
Why?
|
| Laparotomy | 1 | 1998 | 456 | 0.010 |
Why?
|
| Sex Determination Analysis | 1 | 1995 | 46 | 0.010 |
Why?
|
| Tretinoin | 1 | 1999 | 519 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1998 | 562 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12661 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1977 | 357 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 4058 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2849 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1979 | 496 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 2222 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1995 | 120 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1996 | 313 | 0.010 |
Why?
|
| Arteries | 1 | 1980 | 1122 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1242 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1977 | 616 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2002 | 1265 | 0.010 |
Why?
|
| Clone Cells | 1 | 1998 | 1657 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1997 | 717 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1994 | 42 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1983 | 6188 | 0.010 |
Why?
|
| Health Surveys | 1 | 2004 | 4037 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1995 | 223 | 0.010 |
Why?
|
| Self Concept | 1 | 1980 | 1046 | 0.010 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 1994 | 138 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1697 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7798 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1977 | 2010 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1993 | 6826 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1985 | 3182 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1979 | 1467 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 15908 | 0.010 |
Why?
|
| RNA | 1 | 2002 | 2713 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 1994 | 395 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 5866 | 0.010 |
Why?
|
| Receptors, Interferon | 1 | 1992 | 115 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1977 | 1226 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2000 | 1745 | 0.010 |
Why?
|
| Genomics | 1 | 2008 | 5822 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1991 | 260 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2817 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1984 | 2185 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 7196 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 8618 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 1788 | 0.010 |
Why?
|
| Salpingostomy | 1 | 1990 | 8 | 0.010 |
Why?
|
| Peptides | 1 | 2003 | 4354 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1994 | 1646 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1990 | 1972 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 1141 | 0.010 |
Why?
|
| Thiazoles | 1 | 1998 | 1517 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1982 | 4533 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1994 | 341 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 1984 | 3066 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1986 | 726 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1990 | 63 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1993 | 1248 | 0.010 |
Why?
|
| Anxiety | 1 | 2005 | 4570 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2000 | 4160 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1980 | 2909 | 0.010 |
Why?
|
| Pain | 1 | 2004 | 5061 | 0.010 |
Why?
|
| Comorbidity | 2 | 1994 | 10505 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1991 | 414 | 0.010 |
Why?
|
| Luteinizing Hormone | 2 | 1982 | 820 | 0.000 |
Why?
|
| Granulocytes | 1 | 1991 | 551 | 0.000 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 1988 | 37 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1981 | 3418 | 0.000 |
Why?
|
| Meningeal Neoplasms | 1 | 1978 | 1245 | 0.000 |
Why?
|
| Receptors, Somatomedin | 1 | 1988 | 57 | 0.000 |
Why?
|
| Oxygen | 1 | 2000 | 4226 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 1623 | 0.000 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 1988 | 56 | 0.000 |
Why?
|
| Platelet Count | 1 | 1991 | 780 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1988 | 455 | 0.000 |
Why?
|
| Heart | 1 | 2000 | 4403 | 0.000 |
Why?
|
| Prevalence | 2 | 1994 | 15689 | 0.000 |
Why?
|
| Monitoring, Physiologic | 2 | 1985 | 1779 | 0.000 |
Why?
|
| Placental Lactogen | 1 | 1986 | 17 | 0.000 |
Why?
|
| Interpersonal Relations | 2 | 1985 | 1438 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1993 | 1239 | 0.000 |
Why?
|
| Affect | 1 | 1994 | 1486 | 0.000 |
Why?
|
| Health Services Needs and Demand | 1 | 1994 | 1400 | 0.000 |
Why?
|
| Dyspnea | 1 | 1994 | 1347 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2533 | 0.000 |
Why?
|
| Education | 1 | 1989 | 534 | 0.000 |
Why?
|
| Obesity, Morbid | 1 | 1996 | 1276 | 0.000 |
Why?
|
| Mood Disorders | 1 | 1992 | 1127 | 0.000 |
Why?
|
| Chronic Disease | 1 | 2000 | 9311 | 0.000 |
Why?
|
| Flupenthixol | 1 | 1984 | 11 | 0.000 |
Why?
|
| Fluphenazine | 1 | 1984 | 35 | 0.000 |
Why?
|
| Monocytes | 1 | 1994 | 2565 | 0.000 |
Why?
|
| Paternity | 1 | 1984 | 14 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1988 | 836 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1985 | 490 | 0.000 |
Why?
|
| Prolactin | 1 | 1986 | 625 | 0.000 |
Why?
|
| Reoperation | 1 | 1994 | 4300 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1992 | 6224 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1994 | 2768 | 0.000 |
Why?
|
| Binding Sites | 1 | 1992 | 6051 | 0.000 |
Why?
|
| Exercise | 1 | 2000 | 5886 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1984 | 493 | 0.000 |
Why?
|
| Hypertension, Pulmonary | 1 | 1994 | 1580 | 0.000 |
Why?
|
| Complement Activating Enzymes | 1 | 1982 | 22 | 0.000 |
Why?
|
| Respiration, Artificial | 1 | 1994 | 2630 | 0.000 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1994 | 1462 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1983 | 412 | 0.000 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1983 | 335 | 0.000 |
Why?
|
| Complement C1q | 1 | 1982 | 93 | 0.000 |
Why?
|
| Ranidae | 1 | 1982 | 32 | 0.000 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1981 | 29 | 0.000 |
Why?
|
| Thyroxine | 1 | 1984 | 665 | 0.000 |
Why?
|
| Interview, Psychological | 1 | 1984 | 809 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1984 | 850 | 0.000 |
Why?
|
| Veterans | 1 | 1994 | 2649 | 0.000 |
Why?
|
| Random Allocation | 1 | 1985 | 2392 | 0.000 |
Why?
|
| Depressive Disorder | 1 | 1993 | 3735 | 0.000 |
Why?
|
| Delayed-Action Preparations | 1 | 1984 | 962 | 0.000 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 1981 | 241 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1993 | 5491 | 0.000 |
Why?
|
| Dehydroepiandrosterone | 1 | 1981 | 258 | 0.000 |
Why?
|
| Clomiphene | 1 | 1979 | 71 | 0.000 |
Why?
|
| Congenital Abnormalities | 1 | 1984 | 709 | 0.000 |
Why?
|
| Biological Assay | 1 | 1982 | 626 | 0.000 |
Why?
|
| Polyethylene Glycols | 1 | 1984 | 1182 | 0.000 |
Why?
|
| Immunoassay | 1 | 1982 | 744 | 0.000 |
Why?
|
| Reference Standards | 1 | 1982 | 1002 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1984 | 1170 | 0.000 |
Why?
|
| Health Education | 1 | 1984 | 1049 | 0.000 |
Why?
|
| Communication | 1 | 1990 | 3849 | 0.000 |
Why?
|
| Testis | 1 | 1979 | 792 | 0.000 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1979 | 701 | 0.000 |
Why?
|
| Insulin | 1 | 1988 | 6593 | 0.000 |
Why?
|
| Cerebellar Neoplasms | 1 | 1978 | 586 | 0.000 |
Why?
|
| Body Weight | 1 | 1979 | 4614 | 0.000 |
Why?
|
| Testosterone | 1 | 1979 | 2472 | 0.000 |
Why?
|
| Rats | 1 | 1982 | 23717 | 0.000 |
Why?
|